Garrison Point Advisors’s Novo Nordisk NVO Stock Holding History

Garrison Point Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Hold	33,268	–	–	0.65%	42
2026 Q1	$1.22M	Sell	33,268 -3,000	-8%	-$142K	0.56%	52
2025 Q4	$1.85M	Hold	36,268	–	–	0.82%	30
2025 Q3	$2.01M	Hold	36,268	–	–	0.84%	27
2025 Q2	$2.5M	Hold	36,268	–	–	1.15%	17
2025 Q1	$2.52M	Hold	36,268	–	–	1.22%	17
2024 Q4	$3.12M	Buy	+36,268	New	+$3.92M	1.48%	14

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Garrison Point Advisors's NVO Position: Q2 2026 in Review

Garrison Point Advisors held its Novo Nordisk (NVO) position steady in Q2 2026 at 33,268 shares worth $1.59M. The position accounts for 0.65% of the portfolio, ranked #42.

Garrison Point Advisors first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.12M in Q4 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Garrison Point Advisors held 33,268 shares of Novo Nordisk worth $1.59M as of Q2 2026.
Garrison Point Advisors left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.65% of Garrison Point Advisors's portfolio in Q2 2026, its #42 holding.
Garrison Point Advisors first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
Garrison Point Advisors's Novo Nordisk position peaked at $3.12M in Q4 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Garrison Point Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.